Martha M Kirstein1, Steffen Marquardt2, Nils Jedicke3, Silke Marhenke3, Wolfgang Koppert4, Michael P Manns3, Frank Wacker2, Arndt Vogel3. 1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. kirstein.martha@mh-hannover.de. 2. Institute for Radiology, Hannover Medical School, Hannover, Germany. 3. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. 4. Department of Anesthesiology, Hannover Medical School, Hannover, Germany.
Abstract
BACKGROUND: Chemosaturation with percutaneous hepatic perfusion (CS-PHP; hepatic CHEMOSAT® delivery system; Delcath Systems Inc, USA) is a novel medical device, which delivers high doses of melphalan directly to the liver in patients with primary and secondary liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. The aim of this study was to analyze the safety and efficacy of the second-generation CS-PHP after 54 treatments at Hannover Medical School, Germany. METHODS: Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumors (RECIST1.1). Overall survival (OS), progression-free survival (PFS), and hepatic PFS (hPFS) were analyzed using the Kaplan-Meier estimation. RESULTS: 29 patients were treated with CS-PHP as last-line therapy up to five sessions. 19 patients had unresectable hepatic metastases from solid tumors [ocular melanoma (OM) n = 11; colorectal carcinoma n = 2; pancreatic adenocarcinoma n = 2; periampular carcinoma n = 2; breast and endometrial cancer each n = 1] and 10 patients were diagnosed with hepatocellular or cholangiocarcinoma (HCC/CCA). ORR was 19.2%. Patients with OM had the highest ORR (33.3%). Similar to patients with OM, patients with hepatobiliary tumors had durable disease stabilization (40%). Median OS, PFS, and hPFS were 261, 117, and 135 days, respectively. Tumor volume negatively correlated with OS. Complications and toxicities included thrombocytopenia, cardiovascular events, ulcerous bleeding, and edema. CONCLUSION: Second-generation CS-PHP seems to be effective and tolerable. Patient selection based on tumor volume and entity is of importance. Particularly, patients with OM and hepatobiliary tumors represent promising candidates for CS-PHP.
BACKGROUND: Chemosaturation with percutaneous hepatic perfusion (CS-PHP; hepatic CHEMOSAT® delivery system; Delcath Systems Inc, USA) is a novel medical device, which delivers high doses of melphalan directly to the liver in patients with primary and secondary liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. The aim of this study was to analyze the safety and efficacy of the second-generation CS-PHP after 54 treatments at Hannover Medical School, Germany. METHODS: Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumors (RECIST1.1). Overall survival (OS), progression-free survival (PFS), and hepatic PFS (hPFS) were analyzed using the Kaplan-Meier estimation. RESULTS: 29 patients were treated with CS-PHP as last-line therapy up to five sessions. 19 patients had unresectable hepatic metastases from solid tumors [ocular melanoma (OM) n = 11; colorectal carcinoma n = 2; pancreatic adenocarcinoma n = 2; periampular carcinoma n = 2; breast and endometrial cancer each n = 1] and 10 patients were diagnosed with hepatocellular or cholangiocarcinoma (HCC/CCA). ORR was 19.2%. Patients with OM had the highest ORR (33.3%). Similar to patients with OM, patients with hepatobiliary tumors had durable disease stabilization (40%). Median OS, PFS, and hPFS were 261, 117, and 135 days, respectively. Tumor volume negatively correlated with OS. Complications and toxicities included thrombocytopenia, cardiovascular events, ulcerous bleeding, and edema. CONCLUSION: Second-generation CS-PHP seems to be effective and tolerable. Patient selection based on tumor volume and entity is of importance. Particularly, patients with OM and hepatobiliary tumors represent promising candidates for CS-PHP.
Authors: Marybeth S Hughes; Jonathan Zager; Mark Faries; H Richard Alexander; Richard E Royal; Bradford Wood; Junsung Choi; Kevin McCluskey; Eric Whitman; Sanjiv Agarwala; Gary Siskin; Charles Nutting; Mary Ann Toomey; Carole Webb; Tatiana Beresnev; James F Pingpank Journal: Ann Surg Oncol Date: 2015-11-23 Impact factor: 5.344
Authors: H Richard Alexander; David L Bartlett; Steven K Libutti; James F Pingpank; Douglas L Fraker; Richard Royal; Seth M Steinberg; Cynthia B Helsabeck; Tatiana H Beresneva Journal: Ann Surg Oncol Date: 2009-05-12 Impact factor: 5.344
Authors: L B J van Iersel; H Gelderblom; A L Vahrmeijer; E L van Persijn van Meerten; F G J Tijl; H Putter; H H Hartgrink; P J K Kuppen; J W R Nortier; R A E M Tollenaar; C J H van de Velde Journal: Ann Oncol Date: 2008-02-27 Impact factor: 32.976
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Steffen Marquardt; Martha M Kirstein; Roland Brüning; Martin Zeile; Pier Francesco Ferrucci; Warner Prevoo; Boris Radeleff; Hervé Trillaud; Lambros Tselikas; Emilio Vicente; Philipp Wiggermann; Michael P Manns; Arndt Vogel; Frank K Wacker Journal: Eur Radiol Date: 2018-09-25 Impact factor: 5.315
Authors: T Susanna Meijer; Lioe-Fee de Geus-Oei; Christian H Martini; Fred G J Tijl; M Elske Sitsen; Arian R van Erkel; Rutger W van der Meer; Ellen Kapiteijn; Alexander L Vahrmeijer; Mark C Burgmans Journal: Diagn Interv Radiol Date: 2019-11 Impact factor: 2.630
Authors: C L A Dewald; L S Becker; S K Maschke; T C Meine; T A Alten; M M Kirstein; A Vogel; F K Wacker; B C Meyer; J B Hinrichs Journal: Clin Exp Metastasis Date: 2020-10-09 Impact factor: 5.150
Authors: Cornelia L A Dewald; Mia-Maria Warnke; Roland Brüning; Martin A Schneider; Peter Wohlmuth; Jan B Hinrichs; Anna Saborowski; Arndt Vogel; Frank K Wacker Journal: Cancers (Basel) Date: 2021-12-27 Impact factor: 6.639
Authors: T M L Tong; M K van der Kooij; F M Speetjens; A R van Erkel; R W van der Meer; J Lutjeboer; E L van Persijn van Meerten; C H Martini; R W M Zoethout; F G J Tijl; C U Blank; M C Burgmans; E Kapiteijn Journal: Trials Date: 2022-02-13 Impact factor: 2.279
Authors: T M L Tong; M Samim; E Kapiteijn; T S Meijer; F M Speetjens; R Brüning; T H Schroeder; S El-Sanosy; H Maschke; F K Wacker; A Vogel; C L A Dewald; J J Goeman; M C Burgmans Journal: Cardiovasc Intervent Radiol Date: 2022-08-03 Impact factor: 2.797